EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease

Erez Magiel iD, Melanie Shanie Roitman, Barak Pflantzer, Roni Loebenstein Dagan, Roni Sharon iD, Abdualla Watad, Nicola Maggio, Saar Anis

Headache: The Journal of Head and Face Pain · 2026-06 · 66 (6) · 1244-1249

DOI: 10.1111/head.70063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 09.04.2026. Verfasst von Erez Magiel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Department, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Antibodies, Antinuclear, Autoimmune Diseases, Headache. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study evaluates antinuclear antibody (ANA) test performance in identifying rheumatologic conditions as the source of the headache.

Background

ANA testing is widely used to screen for autoimmune diseases in patients with headaches, but its diagnostic utility remains unclear.

Methods

In this retrospective analytic, cross‐sectional study, 539 patients hospitalized with headache at Sheba Medical Center (2007–2022) underwent ANA testing. Data included demographics, ANA titers and patterns, C‐reactive protein levels, and rheumatologic diagnoses confirmed at discharge or follow‐up. Statistical analyses compared clinical features between groups with and without rheumatologic diagnoses.

Results

Rheumatologic diagnoses were confirmed in 9.6% ( n = 52). Affected patients were older (median 54.7 vs. 41.9 years, p < 0.001), had higher ANA positivity (76.9% vs. 41.9%, p < 0.001), and had elevated titers ( p = 0.003). Homogeneous (17.5% vs. 5.4%) and mixed (25.0% vs. 14.2%) staining patterns were more frequent in rheumatologic cases ( p = 0.02). C‐reactive protein levels lacked diagnostic utility except in vasculitis and giant cell arteritis. Notably, 83.6% of ANA‐positive patients had no rheumatologic diagnosis.

Conclusions

Whereas ANA positivity correlates with rheumatologic disease in patients with headache, its low positive predictive value limits utility as a standalone screening tool. Though age was a differentiator in ANA positivity, our findings support that ANA testing should be performed only when there is clinical suspicion for systemic autoimmune disease, regardless of patient age. Overuse may lead to false positives, unnecessary investigations, and resource strain. Clinical context rather than serology should guide autoimmune evaluation in headache management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntinuclearAutoimmune DiseasesHeadacheHumansFemaleMaleCross-Sectional StudiesRetrospective StudiesMiddle AgedAdultC-Reactive ProteinHospitalizationAged

Stichwörter der Autor:innen

anti‐nuclear antibody (ANA)headachevasculitis

Substanzen

Antibodies, AntinuclearC-Reactive Protein

Autor:innen und Institutionen

  • Neurological Department, Sheba Medical Center, Ramat Gan, Israel.
  • Dina Recanati School of Medicine, Reichman University, Herzliya, Israel.
  • Gertner Institute Sheba Medical Center, Ramat-Gan, Israel.
  • Department of Neurology and Neurosurgery, Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Rheumatology, Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Medicine "B" and Zabludowicz Center of Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Erez Magiel, Roni Sharon

Zitieren

APA

Magiel, E., Roitman, M. S., Pflantzer, B., Dagan, R. L., Sharon, R., Watad, A., Maggio, N., & Anis, S. (2026). Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease. Headache: The Journal of Head and Face Pain, 66(6), 1244-1249. https://doi.org/10.1111/head.70063

Vancouver

Magiel E, Roitman MS, Pflantzer B, Dagan RL, Sharon R, Watad A, et al. Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease. Headache: The Journal of Head and Face Pain. 2026;66(6):1244-1249. doi:10.1111/head.70063

BibTeX
@article{Magiel2026,
  author = {Magiel, Erez and Roitman, Melanie Shanie and Pflantzer, Barak and Dagan, Roni Loebenstein and Sharon, Roni and Watad, Abdualla and Maggio, Nicola and Anis, Saar},
  title = {Utility of ANA in hospitalized patients with headache and suspected systemic autoimmune disease},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {6},
  pages = {1244--1249},
  doi = {10.1111/head.70063}
}
Kostenlos starten →